Literature DB >> 17056462

Exogenous endophthalmitis in pediatric age group.

Saba A Al-Rashaed1, Ahmed M Abu El-Asrar.   

Abstract

PURPOSE: To identify the microbiological spectrum and visual outcome of exogenous infectious endophthalmitis in the pediatric age group.
METHODS: We reviewed the medical records of all children 14 years and younger with culture-positive endophthalmitis treated at King Khaled Eye Specialist Hospital and King Abdulaziz University Hospital between January 1, 1980, and December 31, 2004.
RESULTS: Forty-nine children were identified. There were 32 males and 17 females with a mean age of 5.7 +/- 2.8 years (range 1-13 years). Thirty-five (71.4 %) cases occurred after penetrating open globe injuries and the remaining 14 (28.6%) followed ocular surgery. Primary vitrectomy was performed on 29 (59.2%) eyes. The mean follow-up was 28.4 +/- 28.4 months (range 1.2-98.5 months). A single species was isolated in 42 (85.7%) eyes, and multiple organisms in seven (14.3%) with a total of 56 infecting organisms. The most common isolates were Streptococcus species and coagulase-negative Staphylococci comprising 44.6% and 21.4% of the isolates, respectively. Final visual acuity was 20/200 or better in 15 (34.1%), counting fingers in 8 (18.2%), light perception to hand motions in 8 (18.2%), no light perception in 13 (29.5%) eyes, including 3 that have been enucleated or eviscerated, and not available in 5 patients. None of the children who had nonvirulent organisms had a final visual acuity of no light perception compared with 39.4% of children who had virulent organisms (p = 0.011). Visual outcome of counting fingers was attained in 26% of children who were treated with primary vitrectomy compared with 5.9% of children treated with antibiotics alone on presentation (p = 0.0484). Visual outcome was no light perception in 18.5% of children who underwent primary vitrectomy compared with 47.1% of children treated with antibiotics alone.
CONCLUSIONS: The most common organisms identified were Streptococcus species and coagulase-negative Staphylococci. Culture of a nonvirulent organism, and treatment with primary vitrectomy were associated with better visual outcomes. Visual outcomes were generally poor.

Entities:  

Mesh:

Year:  2006        PMID: 17056462     DOI: 10.1080/09273940600954323

Source DB:  PubMed          Journal:  Ocul Immunol Inflamm        ISSN: 0927-3948            Impact factor:   3.070


  7 in total

1.  Pediatric posttraumatic endophthalmitis.

Authors:  Haixiang Wu; Xinyi Ding; Meng Zhang; Gezhi Xu
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-04-12       Impact factor: 3.117

2.  Endophthalmitis: A review of recent trends.

Authors:  Janice R Safneck
Journal:  Saudi J Ophthalmol       Date:  2012-03-03

Review 3.  Pediatric Posttraumatic Endophthalmitis in China for Twenty Years.

Authors:  Yan Sheng; Wen Sun; Yangshun Gu; Andrzej Grzybowski
Journal:  J Ophthalmol       Date:  2017-01-16       Impact factor: 1.909

4.  Endogenous endophthalmitis caused by Staphylococcus capitis.

Authors:  Abdelrahman M Elhusseiny; Muhammad M Shamim; Riley N Sanders; Ahmed B Sallam
Journal:  Am J Ophthalmol Case Rep       Date:  2022-02-10

5.  Paediatric traumatic cataracts in Southwest China: epidemiological profile.

Authors:  Pingping Wang; Qingyu Fu; Hongbo Yin; Lin Wang; Longqian Liu
Journal:  BMC Ophthalmol       Date:  2022-05-06       Impact factor: 2.086

6.  Pediatric Infectious Endophthalmitis: A 271-case Retrospective Study at a Single Center in China.

Authors:  Meng Zhang; Ge-Zhi Xu; Rui Jiang; Ying-Qin Ni; Ke-Yan Wang; Rui-Ping Gu; Xin-Yi Ding
Journal:  Chin Med J (Engl)       Date:  2016-12-20       Impact factor: 2.628

7.  Post-traumatic endophthalmitis caused by streptococcus species in preschool children: clinical features, antibiotic susceptibilities and outcomes.

Authors:  Yao Yang; Wenjun Sui; Fang Duan; Yujie Li; Jieting Zeng; Zhaoxin Jiang; Manli Liu; Zhaohui Yuan; Xiaofeng Lin
Journal:  Eye (Lond)       Date:  2021-02-24       Impact factor: 3.775

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.